Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natural Killer Group 2 Member A Receptor (NKG2A)
- Target
- NKG2A
- Molecular classification
- C-type lectin-like receptor, Receptor, CD94/NKG2 family
01
Overview
Natural killer group 2 member A (NKG2A) is an inhibitory receptor expressed primarily on natural killer (NK) cells and a subset of CD8+ T cells. It forms a heterodimer with CD94 and binds to HLA-E, delivering inhibitory signals that suppress activation, cytokine production, and cytotoxicity. NKG2A plays a crucial role in regulating immune responses, preventing excessive tissue damage and maintaining self-tolerance. It is a promising target for immunotherapy, particularly in cancer, where tumor cells often upregulate HLA-E to evade immune destruction. Blocking antibodies targeting NKG2A are under investigation to restore anti-tumor immunity.
- Other names
- KLRC1CD159a
02
Mechanism of action
Antibody blockade of NKG2A to restore NK and T cell cytotoxicity.
03
Biological functions
Immune responseInhibition of NK cell cytotoxicityRegulation of CD8+ T cell activityImmune checkpoint
04
Disease associations
CancerViral infectionAutoimmunityInflammation
05
Safety considerations
Potential for autoimmune reactions due to unleashed immune activity.Cytokine release syndrome
06
Interacting drugs
Monoclonal antibodies blocking NKG2A (e.g., Monalizumab)
07
Biomarkers
HLA-E expression levels (as predictive marker for response to NKG2A blockade)NKG2A expression levels on immune cells
Beyond the preview
Go deeper on Natural Killer Group 2 Member A Receptor (NKG2A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Natural Killer Group 2 Member A Receptor (NKG2A).